FORT WORTH, Texas, March 31, 2011 /PRNewswire/ — Recent
information presented at the British Hip Society Annual Conference
held from March 2 -4, 2011 indicates a rise in the failure rate of
the DePuy ASR XL Acetabular Hip Replacement System which was
manufactured and marketed by DePuy Orthopaedics, Inc., a subsidiary
of Johnson & Johnson. The British Orthopaedic Association
has released a summary of the results of the study presented,
stating that the early failure rates “range from 21% revision rate
at 4 years (potentially rising to 35% if all currently known
painful implants progress to revision) to 49% at 6 years for the
ASR XL device.” This summary was included in an article
published on the British Orthopaedic Association’s website entitled
“Large Diameter Metal on Metal Bearing Total Hip Replacements.”
“The DePuy ASR XL Hip Replacement Systems were first sold by
DePuy and Johnson & Johnson in the UK and other countries in
2003. The ASR XL was sold in the United States beginning in 2005.
It now appears that patients who received these implants are
experiencing failures at a staggering rate. The device was recalled
by DePuy Orthopaedics, Inc. on August 24, 2010. Sales of a medical
product with a failure rate of 49% at six years is unconscionable.
Profits over patient safety is unacceptable,” said attorney John
David Hart of the Law Offices of John David Hart who represents
many individuals in the United States who have been injured as a
result of this defective hip replacement system.
DePuy identified reasons for the failure of the hip replacement
system as component loosening, component malalignment, infection,
fracture of the bone, dislocation, metal sensitivity and pain.
Additional complications from the DePuy ASR XL Acetabular Hip
Replacement System may include increased metal ion levels in the
blood, bone staining, necrosis, swelling, nerve damage, tissue
damage and/or muscle damage.
The Law Offices of John David